g260361mmi008.gif
Zynerba Pharmaceuticals, Inc. General Corporate Statement (Form8) - Zynerba Pharmaceuticals (NASDAQ:ZYNE) - Benzinga
Zynerba Pharmaceuticals, Inc. General Corporate Statement (Form8) - Zynerba Pharmaceuticals (NASDAQ:ZYNE) - Benzinga
Zynerba Pharma Receives FDA Guidance For Phase 3 Trial Of Zygel; Street Sees 75% Upside
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
Zynerba: Repeated Trial Failures, Some Post Hoc Success (NASDAQ:ZYNE) | Seeking Alpha
SCYNEXIS Inc names Zynerba Pharmaceuticals Inc CEO Armando Anido to its board
Zynerba Pharma Receives FDA Guidance For Phase 3 Trial Of Zygel; Street Sees 75% Upside
Big medical bet: Why this Philly area pharma company's shares jumped 65 percent in a week
/arc-anglerfish-arc2-prod-pmn.s3.amazonaws.com/public/YST6UFBNEVBAXNOUKDYSHHF4AM.PNG "Synthetic CBD from Main Line biotech gets fast track status from FDA")
Synthetic CBD from Main Line biotech gets fast track status from FDA
Zygel - Zynerba
Should You Buy Zynerba Pharmaceuticals Inc (ZYNE) Stock on Thursday?
FDA urged to approve Sarepta DMD drug by dozens of medical experts - STAT
Zygel's anticipated impact on underserved fragile X syndrome market
Shares of Devon-Based Zynerba Pharmaceuticals Surge After Firm Wins Patent
Zynerba Pharmaceuticals - Whether They've Cracked The Code For Fully Methylated FX Syndrome Patients (NASDAQ:ZYNE) | Seeking Alpha
Zynerba Pharmaceuticals CEO welcomes FDA approval of cannabinoid products
Zynerba Stock is a Medical Cannabis Investment You Can Feel Good About
Zynerba Pharmaceuticals Inc's CBD skin gel Zygel offers a potential goldmine of therapies for Fragile X syndrome, and other conditions
